Cited by 883

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Pharmacokinetics of selective serotonin reuptake inhibitors

Hiemke, Christoph, Härtter, Sebastian·2000·Pharmacology & Therapeutics

DOI 10.1016/s0163-7258(99)00048-0

Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0163-7258(99)00048-0

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology
Goodnick, P. J., & Goldstein, B. J. (1998) · Journal of Psychopharmacology · doi:10.1177/0269881198012003021 · Cited by 183
A comparison of the post‐marketing safety of four selective serotonin re‐uptake inhibitors including the investigation of symptoms occurring on withdrawal
PRICE, J. S., WALLER, P. C., WOOD, S. M., & MACKAY, A. V. P. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.00498.x · Cited by 171

Show all 2 references

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Effects of Chronic Fluoxetine in Animal Models of Anxiety and Depression
Dulawa, S. C., Holick, K. A., Gundersen, B., & Hen, R. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300433 · Cited by 671
The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care
Hirschfeld, R. M. A. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0609 · Cited by 661
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612
Why are women so vulnerable to anxiety, trauma-related and stress-related disorders? The potential role of sex hormones
Li, S. H., & Graham, B. M. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30358-3 · Cited by 579
Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
Aquatic ecotoxicology of fluoxetine
Brooks, B. W., Foran, C. M., Richards, S. M., Weston, J., Turner, P. K., Stanley, J. K., Solomon, K. R., Slattery, M., & La Point, T. W. (2003) · Toxicology Letters · doi:10.1016/s0378-4274(03)00066-3 · Cited by 443
Astroglial Plasticity in the Hippocampus is Affected by Chronic Psychosocial Stress and Concomitant Fluoxetine Treatment
Czéh, B., Simon, M., Schmelting, B., Hiemke, C., & Fuchs, E. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300982 · Cited by 434
Self-citation
A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000023 · Cited by 295
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Evidence‐based treatment of depression in patients with cancer
Li, M., Fitzgerald, P., & Rodin, G. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7372 · Cited by 236
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions
Ramasubbu, R., Taylor, V. H., Samaan, Z., Sockalingham, S., Li, M., Patten, S., Rodin, G., Schaffer, A., Beaulieu, S., & McIntyre, R. S. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400110 · Cited by 206
The Antidepressant Sertraline Provides a Promising Therapeutic Option for Neurotropic Cryptococcal Infections
Zhai, B., Wu, C., Wang, L., Sachs, M. S., & Lin, X. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00212-12 · Cited by 205
Psychiatric Morbidity and Other Factors Affecting Treatment Adherence in Pulmonary Tuberculosis Patients
Pachi, A., Bratis, D., Moussas, G., & Tselebis, A. (2013) · Tuberculosis Research and Treatment · doi:10.1155/2013/489865 · Cited by 185
A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: Do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression?
Walker, F. R. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.10.002 · Cited by 175
Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
Wang, J., Liu, Z., Wang, W., Chen, X., Shu, Y., He, N., & Zhou, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116513 · Cited by 147
Selective Serotonin Reuptake Inhibitor Antidepressant Treatment Discontinuation Syndrome: A Review of the Clinical Evidence and the Possible Mechanisms Involved
Renoir, T. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00045 · Cited by 107
Chronic psychosocial stress and citalopram modulate the expression of the glial proteins GFAP and NDRG2 in the hippocampus
Araya-Callís, C., Hiemke, C., Abumaria, N., & Flugge, G. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2741-x · Cited by 109
Self-citation
Intranasal delivery of paroxetine nanoemulsion via the olfactory region for the management of depression: Formulation, behavioural and biochemical estimation
Pandey, Y. R., Kumar, S., Gupta, B. K., Ali, J., & Baboota, S. (2016) · Nanotechnology · doi:10.1088/0957-4484/27/2/025102 · Cited by 96
Premature Ejaculation Associated with Citalopram Withdrawal
Adson, D. E., & Kotlyar, M. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1d214 · Cited by 50
Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial
Hjorth, O. R., Frick, A., Gingnell, M., Hoppe, J. M., Faria, V., Hultberg, S., Alaie, I., Månsson, K. N. T., Rosén, J., Reis, M., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01682-3 · Cited by 46
Antifungal and antibiofilm activities of selective serotonin reuptake inhibitors alone and in combination with fluconazole
TEKİNTAŞ, Y., TEMEL, A., ATEŞ, A., ERAÇ, B., METİN, D. Y., HİLMİOĞLU POLAT, S., & HOŞGÖR LİMONCU, M. (2020) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2019.65481 · Cited by 16
Characteristics of Escitalopram Discontinuation Syndrome: A Preliminary Study
Yasui-Furukori, N., Hashimoto, K., Tsuchimine, S., Tomita, T., Sugawara, N., Ishioka, M., & Nakamura, K. (2016) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000139 · Cited by 13
Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy
Hjorth, O., Frick, A., Gingnell, M., Engman, J., Björkstrand, J., Faria, V., Alaie, I., Carlbring, P., Andersson, G., Jonasson, M., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02187-3 · Cited by 13
Effects of selective serotonin reuptake inhibitors on auditory processing
Gopal, K., Daly, D. M., Daniloff, R. G., & Pennartz, L. (1999) · The Journal of the Acoustical Society of America · doi:10.1121/1.426386 · Cited by 3

Authors: Hiemke, C., & Härtter, S.
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 2000-01
Volume: 85
Issue: 1
Pages: 11-28
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/s0163-7258(99)00048-0
OpenAlex: W2090977130
Cited by: 883
References: 2
FWCI: 19.43
Type: journal article
Language: en
Open access: closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Pharmacokinetics of selective serotonin reuptake inhibitors

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources